Efficacy And Safety Of The Hydrus Implant Combined With Phacoemulsification: A Retrospective Multicenter Study
Published 2026 - 44th Congress of the ESCRS
Reference: PP04.018 | Type: Free paper | DOI: 10.82333/cjy4-2z48
Authors: Dr Alice Grise-Dulac* 1 , Dr Ana Miguel 2 , A/Prof. Antoine Labbe 3 , Dr Damien Gatinel 1 , A/Prof. Florent Aptel 4 , A/Prof. Philippe Denis 5
1Fondation Rothschild,paris,France, 2hopital privé de la baie,Avranches,France, 3hopital des XV XX,paris,France, 4Centre d'ophtalmologie Visis,Perpignan,France, 5Hôpital de la Croix-Rousse,Lyon,France
Purpose
To report one-year outcomes from a multicenter cohort of patients with primary open-angle glaucoma (POAG) who underwent phacoemulsification combined with Hydrus® microstent implantation.
Setting
Multicenter study conducted in tertiary referral ophthalmology centers in France.
Methods
This retrospective study included 158 eyes of 109 patients with POAG who underwent combined Hydrus implantation and phacoemulsification between March 2024 and December 2025 in tertiary referral centers in France. We respected Helsinki’s Ethics principles and obtained an ethics CNIL declaration number ***. The primary outcome measure was intraocular pressure (IOP). Follow-up visits were conducted at day 7, month 1, month 3, month 6, and 12 months postoperatively. The number of antiglaucoma medications and intraoperative and postoperative complications were recorded.
Results
A total of 159 eyes from 110 patients were included. Mean IOP decreased from 16.2 mmHg preoperatively (N = 158) to 13.8 mmHg at 6 months (N = 48) and 15.3 mmHg at 12 months (N = 20). The mean number of hypotensive medications decreased from 1.9 preoperatively to 1.3 at 6 months (N = 51) and 1.6 at 12 months (N = 20). Reported complications included transient IOP spikes and self-resolving hyphema. No serious intraoperative or postoperative adverse events were reported. Among patients with 12-month follow-up, none required additional glaucoma surgery during the study period.
Conclusions
These results are the first reported in France and should be considered preliminary. They were obtained in tertiary university referral centers with several surgeons, which may partly explain the outcomes. Longer follow-up will be necessary.
These preliminary results suggest a favorable safety profile of the Hydrus implant, with no serious adverse events reported, and a trend toward IOP reduction as early as 3 months postoperatively.
The combination of Hydrus implantation with phacoemulsification resulted in a 9.4% reduction in IOP and a mean decrease of 0.3 antiglaucoma medications at 12 months. These findings support the potential role of this therapeutic option in glaucoma management and provide encouraging perspectives for future use.